The European Patent Office published patent application EP3982998A1 on March 25, 2026, for Alkermes Pharma Ireland Limited. The patent covers compositions and methods for subcutaneous administration of cancer immunotherapy agents, with IPC classifications including A61K 38/17 (cytokines), A61K 38/20 (interleukins), C07K 14/715 (cytokine receptor proteins), C07K 14/55 (interleukin receptors), and A61P 35/00 (antineoplastic agents). The designated states cover all European Patent Convention contracting states.\n\nThis is a routine patent publication that establishes intellectual property rights without imposing regulatory compliance obligations. Pharmaceutical and biotechnology companies conducting freedom-to-operate analyses should review the patent claims for potential licensing considerations. The patent grants Alkermes exclusive rights to the disclosed subcutaneous immunotherapy formulations and methods.